U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C15H12N2O2
Molecular Weight 252.2685
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PHENYTOIN

SMILES

c1ccc(cc1)C2(c3ccccc3)C(=NC(=N2)O)O

InChI

InChIKey=CXOFVDLJLONNDW-UHFFFAOYSA-N
InChI=1S/C15H12N2O2/c18-13-15(17-14(19)16-13,11-7-3-1-4-8-11)12-9-5-2-6-10-12/h1-10H,(H2,16,17,18,19)

HIDE SMILES / InChI

Molecular Formula C15H12N2O2
Molecular Weight 252.2685
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020450s020lbl.pdf

Phenytoin is an anti-epileptic drug. Phenytoin has been used with much clinical success against all types of epileptiform seizures, except petit mal epilepsy. Phenytoin is a available for oral administration (tablets, capsules, suspension). CEREBYX® (fosphenytoin sodium injection) is a prodrug intended for parenteral administration; its active metabolite is phenytoin. CEREBYX should be used only when oral phenytoin administration is not possible. Although several potential targets for phenytoin action have been identified within the CNS (Na-K-ATPase, the GABAA receptor complex, ionotropic glutamate receptors, calcium channels and sigma binding sites) to date, though, the best evidence hinges on the inhibition of voltage-sensitive Na+ channels in the plasma membrane of neurons undergoing seizure activity.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
DILANTIN-125

Approved Use

Dilantin (phenytoin) is indicated for the control of tonic-clonic (grand mal) and psychomotor (temporal lobe) seizures

Launch Date

-536025600000
Primary
CEREBYX

Approved Use

CEREBYX is indicated for the control of generalized tonic-clonic status epilepticus and prevention and treatment of seizures occurring during neurosurgery. CEREBYX can also be substituted, short-term, for oral phenytoin. CEREBYX should be used only when oral phenytoin administration is not possible. CEREBYX must not be given orally.

Launch Date

839116800000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1.176 μg/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PHENYTOIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
32.172 μg × h/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PHENYTOIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
15.49 h
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PHENYTOIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
600 mg single, oral
Highest studied dose
unhealthy, 31 years
20 g single, oral
Overdose
Dose: 20 g
Route: oral
Route: single
Dose: 20 g
Sources:
unhealthy, 41 years
Health Status: unhealthy
Age Group: 41 years
Sex: F
Sources:
Other AEs: Sinus bradycardia, Hypotension...
Other AEs:
Sinus bradycardia (1 patient)
Hypotension (severe, 1 patient)
Sources:
5 g single, oral
Overdose
Dose: 5 g
Route: oral
Route: single
Dose: 5 g
Sources:
unhealthy, 49 years
Health Status: unhealthy
Age Group: 49 years
Sex: M
Sources:
Other AEs: Acute respiratory failure...
Other AEs:
Acute respiratory failure (1 patient)
Sources:
60 mg/kg multiple, intravenous
Overdose
Dose: 60 mg/kg
Route: intravenous
Route: multiple
Dose: 60 mg/kg
Sources:
unhealthy, 7 years
Health Status: unhealthy
Age Group: 7 years
Sex: M
Sources:
Other AEs: Encephalopathy...
Other AEs:
Encephalopathy (1 patient)
Sources:
2 g single, oral
Overdose
Dose: 2 g
Route: oral
Route: single
Dose: 2 g
Sources:
unhealthy, adult
Other AEs: Nystagmus, Ataxia...
Other AEs:
Nystagmus (grade 5)
Ataxia (grade 5)
Dysarthria (grade 5)
Tremor (grade 5)
Hyperreflexia (grade 5)
Lethargy (grade 5)
Slurred speech (grade 5)
Blurred vision (grade 5)
Nausea (grade 5)
Vomiting (grade 5)
Sources:
10 mg/kg single, intramuscular
Dose: 10 mg/kg
Route: intramuscular
Route: single
Dose: 10 mg/kg
Sources:
unhealthy, adult
Other AEs: Hypotension, Cardiac arrhythmias...
Other AEs:
Hypotension (severe)
Cardiac arrhythmias
Sources:
10 mg/kg single, intravenous
Dose: 10 mg/kg
Route: intravenous
Route: single
Dose: 10 mg/kg
Sources:
unhealthy, adult
Other AEs: Hypotension, Cardiac arrhythmias...
Other AEs:
Hypotension (severe)
Cardiac arrhythmias
Sources:
AEs

AEs

AESignificanceDosePopulation
Sinus bradycardia 1 patient
20 g single, oral
Overdose
Dose: 20 g
Route: oral
Route: single
Dose: 20 g
Sources:
unhealthy, 41 years
Health Status: unhealthy
Age Group: 41 years
Sex: F
Sources:
Hypotension severe, 1 patient
20 g single, oral
Overdose
Dose: 20 g
Route: oral
Route: single
Dose: 20 g
Sources:
unhealthy, 41 years
Health Status: unhealthy
Age Group: 41 years
Sex: F
Sources:
Acute respiratory failure 1 patient
5 g single, oral
Overdose
Dose: 5 g
Route: oral
Route: single
Dose: 5 g
Sources:
unhealthy, 49 years
Health Status: unhealthy
Age Group: 49 years
Sex: M
Sources:
Encephalopathy 1 patient
60 mg/kg multiple, intravenous
Overdose
Dose: 60 mg/kg
Route: intravenous
Route: multiple
Dose: 60 mg/kg
Sources:
unhealthy, 7 years
Health Status: unhealthy
Age Group: 7 years
Sex: M
Sources:
Ataxia grade 5
2 g single, oral
Overdose
Dose: 2 g
Route: oral
Route: single
Dose: 2 g
Sources:
unhealthy, adult
Blurred vision grade 5
2 g single, oral
Overdose
Dose: 2 g
Route: oral
Route: single
Dose: 2 g
Sources:
unhealthy, adult
Dysarthria grade 5
2 g single, oral
Overdose
Dose: 2 g
Route: oral
Route: single
Dose: 2 g
Sources:
unhealthy, adult
Hyperreflexia grade 5
2 g single, oral
Overdose
Dose: 2 g
Route: oral
Route: single
Dose: 2 g
Sources:
unhealthy, adult
Lethargy grade 5
2 g single, oral
Overdose
Dose: 2 g
Route: oral
Route: single
Dose: 2 g
Sources:
unhealthy, adult
Nausea grade 5
2 g single, oral
Overdose
Dose: 2 g
Route: oral
Route: single
Dose: 2 g
Sources:
unhealthy, adult
Nystagmus grade 5
2 g single, oral
Overdose
Dose: 2 g
Route: oral
Route: single
Dose: 2 g
Sources:
unhealthy, adult
Slurred speech grade 5
2 g single, oral
Overdose
Dose: 2 g
Route: oral
Route: single
Dose: 2 g
Sources:
unhealthy, adult
Tremor grade 5
2 g single, oral
Overdose
Dose: 2 g
Route: oral
Route: single
Dose: 2 g
Sources:
unhealthy, adult
Vomiting grade 5
2 g single, oral
Overdose
Dose: 2 g
Route: oral
Route: single
Dose: 2 g
Sources:
unhealthy, adult
Cardiac arrhythmias
10 mg/kg single, intramuscular
Dose: 10 mg/kg
Route: intramuscular
Route: single
Dose: 10 mg/kg
Sources:
unhealthy, adult
Hypotension severe
10 mg/kg single, intramuscular
Dose: 10 mg/kg
Route: intramuscular
Route: single
Dose: 10 mg/kg
Sources:
unhealthy, adult
Cardiac arrhythmias
10 mg/kg single, intravenous
Dose: 10 mg/kg
Route: intravenous
Route: single
Dose: 10 mg/kg
Sources:
unhealthy, adult
Hypotension severe
10 mg/kg single, intravenous
Dose: 10 mg/kg
Route: intravenous
Route: single
Dose: 10 mg/kg
Sources:
unhealthy, adult
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no
no
weak
yes [IC50 145 uM]
yes [IC50 280 uM]
yes [IC50 607 uM]
yes
yes
likely (co-administration study)
Comment: See https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/084427s042lbl.pdf#page=10
yes
likely (co-administration study)
Comment: See https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/084427s042lbl.pdf#page=10
yes
likely (co-administration study)
Comment: See https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/084427s042lbl.pdf#page=11
Page: 46
yes
likely (co-administration study)
Comment: See https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/084427s042lbl.pdf#page=9
yes
likely (co-administration study)
Comment: See https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/084427s042lbl.pdf#page=11
yes
yes (co-administration study)
Comment: mean AUC(0-24) of losartan was insignificantly increased by 17% when losartan was coadministered with phenytoin. See more on https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/084427s042lbl.pdf#page=9
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
no
yes
yes
yes
likely (co-administration study)
Comment: See https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/084427s042lbl.pdf#page=9
yes
yes (co-administration study)
Comment: Coadministration of losartan had no effect on the pharmacokinetics of phenytoin. See more on https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/084427s042lbl.pdf#page8
Page: 8
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Harmful effect of megadoses of vitamins: electroencephalogram abnormalities and seizures induced by intravenous folate in drug-treated epileptics.
1975 Jan
The influence of aldosterone and anticonvulsant drugs on electroencephalographic and clinical disturbances induced by the spirolactone derivative, potassium canrenoate.
1975 Jan
Procainamide and phenytoin. Comparative study of their antiarrhythmic effects at apparent therapeutic plasma levels.
1975 Jul
Spasticity due to phenytoin toxicity.
1979 Mar 10
Anticonvulsant-induced suppression of IFN-gamma production by lymphocytes obtained from cervical lymph nodes in glioma-bearing mice.
2000 Apr
Acute fulminant hepatic failure in a woman treated with phenytoin and trimethoprim-sulfamethoxazole.
2000 Dec
Phenytoin, midazolam, and naloxone protect against fentanyl-induced brain damage in rats.
2000 Dec
Phenytoin poisoning after using Chinese proprietary medicines.
2000 Jul
Purple glove syndrome caused by oral administration of phenytoin.
2000 Nov
Activation of cytochrome P450 gene expression in the rat brain by phenobarbital-like inducers.
2000 Sep
Effects of combined administration of zonisamide and valproic acid or phenytoin to nitric oxide production, monoamines and zonisamide concentrations in the brain of seizure-susceptible EL mice.
2000 Sep 15
Drugs for discoid lupus erythematosus.
2001
II. An altered proliferation response due to the anticonvulsant phenytoin (PHT) in epileptic patients.
2001
I. The modulatory effect in genotoxic responses due to age and duration of PHT-therapy in epileptic patients.
2001
Evaluation of the neuroprotective effects of sodium channel blockers after spinal cord injury: improved behavioral and neuroanatomical recovery with riluzole.
2001 Apr
Performance characteristics of four free phenytoin immunoassays.
2001 Apr
Rocuronium-induced neuromuscular blockade is affected by chronic phenytoin therapy.
2001 Apr
Stereoselective determination of p-hydroxyphenyl-phenylhydantoin enantiomers in rat liver microsomal incubates by reversed-phase high-performance liquid chromatography using beta-cyclodextrin as chiral mobile phase additives.
2001 Apr
Decreases in phenytoin hydroxylation activities catalyzed by liver microsomal cytochrome P450 enzymes in phenytoin-treated rats.
2001 Apr
Inhibition of phenytoin hydroxylation in human liver microsomes by several selective serotonin re-uptake inhibitors.
2001 Apr
The teratogenicity of anticonvulsant drugs.
2001 Apr 12
Nitroso-urea-cisplatin-based chemotherapy associated with valproate: increase of haematologic toxicity.
2001 Feb
Determination of the antiepileptics vigabatrin and gabapentin in dosage forms and biological fluids using Hantzsch reaction.
2001 Feb
Refractory idiopathic status epilepticus.
2001 Feb
Cardiac arrest after fast intravenous infusion of phenytoin mistaken for fosphenytoin.
2001 Feb
Antiepileptic drug withdrawal in patients with temporal lobe epilepsy undergoing presurgical video-EEG monitoring.
2001 Feb
Fosphenytoin: pharmacokinetics and tolerance of intramuscular loading doses.
2001 Feb
Glutamate receptor antagonists differentially affect the protective activity of conventional antiepileptics against amygdala-kindled seizures in rats.
2001 Feb
Phenytoin intoxication induced by fluvoxamine.
2001 Feb
Rufinamide: a double-blind, placebo-controlled proof of principle trial in patients with epilepsy.
2001 Feb
Possible function of astrocyte cytochrome P450 in control of xenobiotic phenytoin in the brain: in vitro studies on murine astrocyte primary cultures.
2001 Feb
[Maintenance dose requirement for phenytoin is lowered in genetically impaired drug metabolism independent of concommitant use of other antiepileptics].
2001 Feb 17
[Febrile convulsions, Treatment and prognosis].
2001 Feb 19
Interferon-alpha2a and 13-cis-retinoic acid with radiation treatment for high-grade glioma.
2001 Jan
Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors.
2001 Jan
Electrophysiological and pharmacological properties of the human brain type IIA Na+ channel expressed in a stable mammalian cell line.
2001 Jan
Hair analysis for pharmaceutical drugs. I. Effective extraction and determination of phenobarbital, phenytoin and their major metabolites in rat and human hair.
2001 Jan
Ritonavir-induced carbamazepine toxicity.
2001 Jan
Treatment of nonfebrile status epilepticus in Rochester, Minn, from 1965 through 1984.
2001 Jan
Effects of antiepileptic drugs on rat platelet aggregation: ex vivo and in vitro study.
2001 Jan
Effects of phenytoin on glutathione status and oxidative stress biomarker gene mRNA levels in cultured precision human liver slices.
2001 Jan
Successful treatment of antiepileptic drug hypersensitivity syndrome with intravenous immune globulin.
2001 Jan
[Lamotrigine in refractory partial and general epilepsies].
2001 Jan 1-15
N6-cyclohexyladenosine and 3-(2-carboxypiperazine-4-yl)-1-propenyl-1-phosphonic acid enhance the effect of antiepileptic drugs against induced seizures in mice.
2001 Jan-Apr
Volume-selective proton MR spectroscopy for in-vitro quantification of anticonvulsants.
2001 Mar
Fosphenytoin in infants of extremely low birth weight.
2001 Mar
Influence of retigabine on the anticonvulsant activity of some antiepileptic drugs against audiogenic seizures in DBA/2 mice.
2001 Mar
Phenytoin-induced cleft palate: evidence for embryonic cardiac bradyarrhythmia due to inhibition of delayed rectifier K+ channels resulting in hypoxia-reoxygenation damage.
2001 Mar
Interaction of plasma proteins with cytochromes P450 mediated metabolic reactions: inhibition by human serum albumin and alpha-globulins of the debrisoquine 4-hydroxylation (CYP2D) in liver microsomes of human, hamster and rat.
2001 Mar 8
Efficacy of levetiracetam versus fosphenytoin for the recurrence of seizures after status epilepticus.
2017 Jun
Patents

Sample Use Guides

Dilantin-125® (Phenytoin Oral Suspension, USP), each 5 ml of suspension contains 125 mg of phenytoin: Patients who have received no previous treatment may be started on one teaspoonful (5 mL) of Dilantin-125 Suspension three times daily, and the dose is then adjusted to suit individual requirements. An increase to five teaspoonfuls daily may be made, if necessary.
Route of Administration: Other
Exposure of human adult keratinocytes (HaCaT cells) for 48 h to alkyd nanoemulsions producing phenytoin concentrations of 3.125-200 μg/mL resulted in relative cell viability readings using tetrazolium dye 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide of 100% confirming nontoxicity and suggesting cell proliferation activity.
Substance Class Chemical
Created
by admin
on Fri Jun 25 20:53:11 UTC 2021
Edited
by admin
on Fri Jun 25 20:53:11 UTC 2021
Record UNII
6158TKW0C5
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PHENYTOIN
EP   HSDB   INN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
INN   USAN  
Official Name English
PHENYTOIN [MI]
Common Name English
PHENYTOIN [USP-RS]
Common Name English
EPAMIN
Brand Name English
SM-88 COMPONENT PHENYTOIN
Code English
PHENYTOIN [WHO-DD]
Common Name English
PHENYTOIN [USAN]
Common Name English
LEPITOIN
Common Name English
PHENYTOIN [JAN]
Common Name English
DILANTIN
Brand Name English
NSC-8722
Code English
PHENYTOIN [EP MONOGRAPH]
Common Name English
ZENTROPIL
Common Name English
PHENYTOIN [IARC]
Common Name English
PHENYTOIN [USP MONOGRAPH]
Common Name English
5,5-DIPHENYLHYDANTOIN
Systematic Name English
PHENYTOIN [MART.]
Common Name English
PHENYTOIN [INN]
Common Name English
PHENYTOIN [HSDB]
Common Name English
PHENYTOIN [WHO-IP]
Common Name English
PHENYTOIN [VANDF]
Common Name English
PHENYTOIN [ORANGE BOOK]
Common Name English
PHENYTOINUM [WHO-IP LATIN]
Common Name English
PHENYTOIN [USP]
Common Name English
2,4-IMIDAZOLIDINEDIONE, 5,5-DIPHENYL-
Systematic Name English
Classification Tree Code System Code
WHO-ESSENTIAL MEDICINES LIST 05
Created by admin on Fri Jun 25 20:53:12 UTC 2021 , Edited by admin on Fri Jun 25 20:53:12 UTC 2021
WHO-VATC QN03AB52
Created by admin on Fri Jun 25 20:53:12 UTC 2021 , Edited by admin on Fri Jun 25 20:53:12 UTC 2021
NDF-RT N0000008486
Created by admin on Fri Jun 25 20:53:11 UTC 2021 , Edited by admin on Fri Jun 25 20:53:11 UTC 2021
FDA ORPHAN DRUG 43490
Created by admin on Fri Jun 25 20:53:11 UTC 2021 , Edited by admin on Fri Jun 25 20:53:11 UTC 2021
WHO-VATC QN03AB02
Created by admin on Fri Jun 25 20:53:12 UTC 2021 , Edited by admin on Fri Jun 25 20:53:12 UTC 2021
LIVERTOX 775
Created by admin on Fri Jun 25 20:53:11 UTC 2021 , Edited by admin on Fri Jun 25 20:53:11 UTC 2021
NDF-RT N0000175753
Created by admin on Fri Jun 25 20:53:11 UTC 2021 , Edited by admin on Fri Jun 25 20:53:11 UTC 2021
CFR 21 CFR 862.3350
Created by admin on Fri Jun 25 20:53:11 UTC 2021 , Edited by admin on Fri Jun 25 20:53:11 UTC 2021
NCI_THESAURUS C264
Created by admin on Fri Jun 25 20:53:11 UTC 2021 , Edited by admin on Fri Jun 25 20:53:11 UTC 2021
IARC Phenytoin
WHO-ATC N03AB52
Created by admin on Fri Jun 25 20:53:11 UTC 2021 , Edited by admin on Fri Jun 25 20:53:11 UTC 2021
NCI_THESAURUS C93038
Created by admin on Fri Jun 25 20:53:11 UTC 2021 , Edited by admin on Fri Jun 25 20:53:11 UTC 2021
WHO-ATC N03AB02
Created by admin on Fri Jun 25 20:53:11 UTC 2021 , Edited by admin on Fri Jun 25 20:53:11 UTC 2021
Code System Code Type Description
NDF-RT
N0000190118
Created by admin on Fri Jun 25 20:53:11 UTC 2021 , Edited by admin on Fri Jun 25 20:53:11 UTC 2021
PRIMARY Cytochrome P450 3A Inducers [MoA]
ECHA (EC/EINECS)
200-328-6
Created by admin on Fri Jun 25 20:53:11 UTC 2021 , Edited by admin on Fri Jun 25 20:53:11 UTC 2021
PRIMARY
NDF-RT
N0000191267
Created by admin on Fri Jun 25 20:53:11 UTC 2021 , Edited by admin on Fri Jun 25 20:53:11 UTC 2021
PRIMARY Cytochrome P450 2D6 Inducers [MoA]
PUBCHEM
1775
Created by admin on Fri Jun 25 20:53:11 UTC 2021 , Edited by admin on Fri Jun 25 20:53:11 UTC 2021
PRIMARY
ChEMBL
CHEMBL16
Created by admin on Fri Jun 25 20:53:11 UTC 2021 , Edited by admin on Fri Jun 25 20:53:11 UTC 2021
PRIMARY
NDF-RT
N0000187063
Created by admin on Fri Jun 25 20:53:11 UTC 2021 , Edited by admin on Fri Jun 25 20:53:11 UTC 2021
PRIMARY Cytochrome P450 2C8 Inducers [MoA]
LACTMED
Phenytoin
Created by admin on Fri Jun 25 20:53:11 UTC 2021 , Edited by admin on Fri Jun 25 20:53:11 UTC 2021
PRIMARY
HSDB
3160
Created by admin on Fri Jun 25 20:53:11 UTC 2021 , Edited by admin on Fri Jun 25 20:53:11 UTC 2021
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
PHENYTOIN
Created by admin on Fri Jun 25 20:53:12 UTC 2021 , Edited by admin on Fri Jun 25 20:53:12 UTC 2021
PRIMARY Description: A white, crystalline powder; odourless. Solubility: Practically insoluble in water; sparingly soluble in ethanol (~750 g/l) TS; slightly soluble in ether R. Category: Anticonvulsant. Storage: Phenytoin should be kept in a tightly closed container, protected from light. Definition: Phenytoin contains not less than 98.0% and not more than 101.0% of C15H12N2O2, calculated with reference to thedried substance.
MERCK INDEX
M8703
Created by admin on Fri Jun 25 20:53:11 UTC 2021 , Edited by admin on Fri Jun 25 20:53:11 UTC 2021
PRIMARY Merck Index
NDF-RT
N0000185607
Created by admin on Fri Jun 25 20:53:11 UTC 2021 , Edited by admin on Fri Jun 25 20:53:11 UTC 2021
PRIMARY Cytochrome P450 2C19 Inducers [MoA]
INN
416
Created by admin on Fri Jun 25 20:53:11 UTC 2021 , Edited by admin on Fri Jun 25 20:53:11 UTC 2021
PRIMARY
RXCUI
8183
Created by admin on Fri Jun 25 20:53:11 UTC 2021 , Edited by admin on Fri Jun 25 20:53:11 UTC 2021
PRIMARY RxNorm
CAS
57-41-0
Created by admin on Fri Jun 25 20:53:11 UTC 2021 , Edited by admin on Fri Jun 25 20:53:11 UTC 2021
PRIMARY
WIKIPEDIA
PHENYTOIN
Created by admin on Fri Jun 25 20:53:12 UTC 2021 , Edited by admin on Fri Jun 25 20:53:12 UTC 2021
PRIMARY
USP_CATALOG
1535008
Created by admin on Fri Jun 25 20:53:11 UTC 2021 , Edited by admin on Fri Jun 25 20:53:11 UTC 2021
PRIMARY USP-RS
DRUG BANK
DB00252
Created by admin on Fri Jun 25 20:53:11 UTC 2021 , Edited by admin on Fri Jun 25 20:53:11 UTC 2021
PRIMARY
NDF-RT
N0000191266
Created by admin on Fri Jun 25 20:53:11 UTC 2021 , Edited by admin on Fri Jun 25 20:53:11 UTC 2021
PRIMARY Cytochrome P450 1A2 Inducers [MoA]
EPA CompTox
57-41-0
Created by admin on Fri Jun 25 20:53:11 UTC 2021 , Edited by admin on Fri Jun 25 20:53:11 UTC 2021
PRIMARY
EVMPD
SUB12211MIG
Created by admin on Fri Jun 25 20:53:11 UTC 2021 , Edited by admin on Fri Jun 25 20:53:11 UTC 2021
PRIMARY
NDF-RT
N0000185507
Created by admin on Fri Jun 25 20:53:11 UTC 2021 , Edited by admin on Fri Jun 25 20:53:11 UTC 2021
PRIMARY Cytochrome P450 2C9 Inducers [MoA]
NCI_THESAURUS
C741
Created by admin on Fri Jun 25 20:53:11 UTC 2021 , Edited by admin on Fri Jun 25 20:53:11 UTC 2021
PRIMARY
DRUG CENTRAL
2152
Created by admin on Fri Jun 25 20:53:11 UTC 2021 , Edited by admin on Fri Jun 25 20:53:11 UTC 2021
PRIMARY
IUPHAR
2624
Created by admin on Fri Jun 25 20:53:11 UTC 2021 , Edited by admin on Fri Jun 25 20:53:11 UTC 2021
PRIMARY
FDA UNII
6158TKW0C5
Created by admin on Fri Jun 25 20:53:11 UTC 2021 , Edited by admin on Fri Jun 25 20:53:11 UTC 2021
PRIMARY
NDF-RT
N0000187064
Created by admin on Fri Jun 25 20:53:11 UTC 2021 , Edited by admin on Fri Jun 25 20:53:11 UTC 2021
PRIMARY Cytochrome P450 2B6 Inducers [MoA]
MESH
D010672
Created by admin on Fri Jun 25 20:53:11 UTC 2021 , Edited by admin on Fri Jun 25 20:53:11 UTC 2021
PRIMARY
Related Record Type Details
TRANSPORTER -> SUBSTRATE
SALT/SOLVATE -> PARENT
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
EP
METABOLIC ENZYME -> SUBSTRATE
TRANSPORTER -> INDUCER
BINDER->LIGAND
BINDING
SALT/SOLVATE -> PARENT
METABOLIC ENZYME -> INDUCER
POTENT
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> INDUCER
METABOLIC ENZYME -> INDUCER
METABOLIC ENZYME -> INDUCER
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
Related Record Type Details
METABOLITE -> PARENT
UGT1A isoforms (UGT1A1, UGT1A4, UGT1A6, and UGT1A9) are involved in the glucuronosyltransferase activity of 4?-HPPH in humans
MAJOR
PLASMA
METABOLITE INACTIVE -> PARENT
(1:1) R:S, by CYP2C19
Scientific Literature
METABOLITE INACTIVE -> PARENT
major metabolite, mainly by CYP2C9
MAJOR
Scientific Literature
METABOLITE -> PARENT
MINOR
METABOLITE -> PARENT
MAJOR
Related Record Type Details
IMPURITY -> PARENT
For the calculation of contents, multiply the peak areas by 1.7
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
For the calculation of contents, multiply the peak areas by 1.4
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC Population
PHARMACOKINETIC
Population
PHARMACOKINETIC
Population
PHARMACOKINETIC
Population
PHARMACOKINETIC
Population
PHARMACOKINETIC